根据最新的研究动态（Nature 2020 Apr 30. doi: 10.1038/s41586-020-2286-9.），有69种化合物(包括29种FDA批准的药物、12种临床试验药物和28种临床前化合物)有希望用于新冠肺炎的治疗。进一步研究这些潜在靶向药物相关蛋白靶点，会极大的加速新冠治疗药物的开发。
A11545eEF1A1 Rabbit mAb
Western blot analysis of extracts of various cell lines, using eEF1A1 Rabbit mAb (A11545) at 1：1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 90s.
Immunofluorescence analysis of C6 cells using eEF1A1 Rabbit mAb (A11545) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of NIH-3T3 cells using eEF1A1 Rabbit mAb (A11545) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of U-2 OS cells using eEF1A1 Rabbit mAb (A11545) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
应用：WB, IF 物种：H, M, R
A12677Brd4 Rabbit mAb
Western blot analysis of extracts of various cell lines, using Brd4 Rabbit mAb (A12677) at 1：1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 30s.
Immunohistochemistry of paraffin-embedded human colon using Brd4 Rabbit mAb (A12677) at dilution of 1:100 (40x lens).
应用：WB, IHC 物种：H
A1402VCP Rabbit mAb
Western blot analysis of extracts of various cell lines, using VCP Rabbit mAb (A1402) at 1：1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 10s.
Immunofluorescence analysis of C6 cells using VCP Rabbit mAb (A1402) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of NIH-3T3 cells using VCP Rabbit mAb (A1402) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of U-2 OS cells using VCP Rabbit mAb (A1402) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
应用：WB, IF 物种：H, M, R
A15788[KO Validated] SEC61B Rabbit pAb
Western blot analysis of extracts of various cell lines, using SEC61B antibody (A15788) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 2s.
Western blot analysis of extracts from normal (control) and SEC61B knockout (KO) 293T cells, using SEC61B antibody (A15788) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 1s.
Immunofluorescence analysis of L929 cells using SEC61B antibody (A15788) at dilution of 1:100. Blue: DAPI for nuclear staining.
应用：WB, IF 物种：H, M, R
A19625CRM1 Rabbit mAb
Western blot analysis of extracts of mouse lung, using CRM1 antibody (A19625) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 3min.
Western blot analysis of extracts of various cell lines, using CRM1 antibody (A19625) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 90s.
Immunohistochemistry of paraffin-embedded rat spleen using CRM1 antibody (A19625) at dilution of 1:100 (40x lens).
Immunohistochemistry of paraffin-embedded human liver cancer using CRM1 antibody (A19625) at dilution of 1:100 (40x lens).
Immunohistochemistry of paraffin-embedded mouse spleen using CRM1 antibody (A19625) at dilution of 1:100 (40x lens).
Immunofluorescence analysis of C6 cells using CRM1 antibody (A19625). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of HeLa cells using CRM1 antibody (A19625). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of NIH-3T3 cells using CRM1 antibody (A19625). Blue: DAPI for nuclear staining.
应用：WB, IHC, IF 物种：H, M, R
A4612ACE2 Rabbit mAb
Western blot analysis of extracts of various cell lines, using ACE2 antibody (A4612) at 1:500 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 180s.
Immunohistochemistry of paraffin-embedded mouse kidney using ACE2 Rabbit mAb (A4612) at dilution of 1:100 (40x lens).
应用：WB,IHC 物种：H, M, R
A9126TMPRSS2 Rabbit mAb
Western blot analysis of extracts of various cell lines, using TMPRSS2 Rabbit mAb (A9126) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Enhanced Kit (RM00021).
Exposure time: 3min.
Immunohistochemistry of paraffin-embedded human esophageal using TMPRSS2 Rabbit mAb (A9126) at dilution of 1:100 (40x lens).
应用：WB, IHC 物种：H, M, R
A9208IMPDH2 Rabbit mAb
Western blot analysis of extracts of various cell lines, using IMPDH2 Rabbit mAb (A9208) at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit (RM00020).
Exposure time: 10s.
Immunofluorescence analysis of C6 cells using IMPDH2 Rabbit mAb (A9208) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of NIH-3T3 cells using IMPDH2 Rabbit mAb (A9208) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
Immunofluorescence analysis of U-2 OS cells using IMPDH2 Rabbit mAb (A9208) at dilution of 1:100 (40x lens). Blue: DAPI for nuclear staining.
应用：WB,IF 物种：H, M, R
| 分类 | 靶点 | 病毒相关蛋白 | 化合物名称 | 药物现状 | 参考文献 (PMID或DOI) | ABclonal相关研究工具 |
|---|---|---|---|---|---|---|
| 病毒入侵 | ACE2 | Captopril | Approved (Hypertension) | 9187274 | A4612 | |
| Lisinopril | Approved (Hypertension) | 12540854 | ||||
| Captopril | Approved (Hypertension) | 9187274 | ||||
| Lisinopril | Approved (Hypertension) | 12540854 | ||||
| TMPRSS2 | Camostat | Approved (Pancreatitis) | 22496216 | A9126 | ||
| Nafamostat | Approved (Anticoagulant) | 10.1128/AAC.01043-16 | ||||
| 病毒复制 | Cyclophilin | Compound 2 | Pre-clinical | 30074795 | A5097, A4861, RK01236 | |
| PI4K-IIIβ | Compound 10 | Pre-clinical | 26885694 | A16416 | ||
| 核酸合成 | IMPDH2 | Nsp14 | Mycophenolic acid | Approved (Organ rejection) | 5799033 | A9208 |
| Ribavirin | Approved (Viral infection) | 22555152 | ||||
| Sanglifehrin A | Pre-clinical | 28076787 | ||||
| Merimepodib | Clinical Trial | 10878288 | ||||
| DCTPP1 | Orf9b | ZINC1775962367 | Pre-clinical | 26771665 | ||
| ZINC4326719 | 28145708 | |||||
| ZINC4511851 | 28655422 | |||||
| 转录调节 | BRD2/4 | E | ABBV-744 | Clinical Trial | 31969702 | A12677 |
| dBET6 | Pre-clinical | 29764999 | ||||
| MZ1 | Pre-clinical | 26035625 | ||||
| CPI-0610 | Clinical Trial | 26815195 | ||||
| JQ1 | Pre-clinical | 24391744 | ||||
| RVX-208 | Clinical Trial | 24391744 | ||||
| HDAC2 | Nsp5 | Apicidin | Pre-clinical | 17868033 | A19626 | |
| Valproic Acid | Approved (CNS diseases, Cancer) | 11742974; 12840003; 21874153 | ||||
| DNMT1 | Orf8 | Azacitidine | Approved | 15899874 | A19679 | |
| 出核运输 | XPO1 | Nsp4/9/Orf6 | Selinexor | Approved | 30115935 | A19625 |
| RAE1 | A6713 | |||||
| 翻译调节 | eEF1A | Ternatin 4 | Pre-clinical | 26651998 | A11545 | |
| eIF4E | 4E2RCat | Pre-clinical | 21507972 | A2162 | ||
| eIF4G | A7552, A19990 | |||||
| EIF4E2/H | Nsp2 | Zotatifin | Clinical Trial | 10.1158/1538-7445.AM2019-2698 | A4305 | |
| LARP1 | N | Rapamycin | Approved (Organ rejection) | 15896331 | A4543 | |
| Sapanisertib | Clinical Trial | 21651476 | ||||
| MNK1 | Tomivosertib | Clinical Trial | 29526098; 30643286 | |||
| MNK2 | ||||||
| 线粒体核糖体 | MRPs | Chloramphenicol | Approved (Bacterial infection) | '23148581 | A4945, A4527, A5897, A5979, A13197 | |
| Tigecycline | 28700943 | |||||
| Linezolid | 16127068 | |||||
| 蛋白加工 | ER α-Glucosidase | IHVR-19029 | Clinical Trial | 29253498; 28197304 | A12725, A19876 | |
| GLA | Nsp14 | Migalastat | Approved (Fabry disease) | 10866822 | A5119 | |
| FKBP7/10 | Orf8 | Rapamycin, FK-506 | Approved (Organ rejection) | 15896331; 9806833 | A19870 | |
| PLOD1/2 | Orf8 | Minoxidil | Approved (Hair loss) | 30481795 | ||
| Sec61 | PS3061 | Pre-clinical | 30550790 | A15788 | ||
| 细胞器酸化 | ATP6AP1 | Nsp6 | Bafilomycin A1 | Pre-clinical | 9572882 | A1209 |
| ATP6V1A | M | A14706 | ||||
| 蛋白降解 | CUL2 | Orf10 | Pevonedistat | Clinical Trial | 19360080 | A5076 |
| 受体 | SIGMAR1 | Nsp6 | Chloroquine | Approved (Malaria) | 30042674 | A5479 |
| SIGMAR1 | Nsp6 | E-52862 | Clinical Trial | 22784008 | ||
| SIGMAR1 | Nsp6 | PD-144418 | Pre-clinical | 9144641 | ||
| SIGMAR1 | Nsp6 | RS-PPCC | Pre-clinical | 17328523 | ||
| SIGMAR1 | Nsp6 | PB28 | Pre-clinical | 16891467 | ||
| TMEM97 | Orf9c | Pre-clinical | 16891467 | |||
| SIGMAR1 | Nsp6 | Haloperidol | Approved (CNS diseases) | 7925616 | A5479 | |
| TMEM97 | Orf9c | Approved (CNS diseases) | 7925616 | |||
| F2RL1 | Orf9c | AC-55541 | Pre-clinical | 18720984 | A5103 | |
| F2RL1 | Orf9c | AZ8838 | Pre-clinical | 28445455 | ||
| F2RL1 | Orf9c | GB110 | Pre-clinical | 20873792 | ||
| F2RL1 | Orf9c | AZ3451 | Pre-clinical | 28445455 | ||
| 转运蛋白 | SLC6A15 | Nsp6 | Loratadine | Approved | 25318072 | |
| SLC1A3 | M | UCPH-101 | Pre-clinical | 19161278 | A9712 | |
| ABCC1 | Orf9c | Daunorubicin | Approved (Cancer) | 9647783 | A3027, A11153 | |
| ABCC1 | Orf9c | S-verapamil | Approved (Hypertension) | 17646169 | ||
| 细胞分裂 | NEK9 | Nsp9 | Dabrafenib | Approved (Cancer) | 29112787 | A17806 |
| CEP250 | Nsp13 | WDB002 | Clinical Trial | US Patent US20170097-359A1 | ||
| VCP | Orf10 | CB5083 | Clinical Trial | 26565666 | A1402 | |
| VCP | Orf10 | DBeQ | Pre-clinical | 21383145 | ||
| 细胞骨架 | MARK2/3 | Orf9b | Midostaurin | Approved (Cancer) | 18183025 | A6512 |
| MARK2/3 | Orf9b | Ruxolitinib | Approved (Myelofibrosis) | 22037378 | ||
| 多功能激酶 | CSNK2A2 | N | Silmitasertib | Approved (Cancer) | 21159648; 21174434 | A1616, A13481 |
| TMCB | Pre-clinical | 22115617 | ||||
| PRKACA | Nsp13 | H-89 | Pre-clinical | 2156866 | A0798, AP0557 | |
| 免疫与炎症 | RIPK1 | Nsp12 | Ponatinib | Approved (Cancer) | 25801024 | A19580 |
| TBK1 | Orf9b Nsp13 | ZINC95559591 | Pre-clinical | 23099093 | A3458, AP1026 | |
| PTGES2 | Nsp7 | Indomethacin | Approved (Inflammation, Pain) | 5284360 | A7137, A13440 | |
| 氧化应激 | LOX | Orf8 | CCT 365623 | Pre-clinical | 31070916 | A11504 |
| 能量代谢 | NDUFs | Nsp7, Orf9c | Metformin | Approved (Diabetes) | 24843020 | A4602, A8691, A8013, A12858 |
| 儿茶酚胺代谢 | COMT | Nsp7 | Entacapone | Approved (Parkinson's disease) | 1407012; 9681662 | A4435, A18085 |
